Focus Taiwan App
Download

Adimmune's COVID-19 vaccine could soon enter clinical trial

08/17/2020 08:21 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Aug. 17 (CNA) An experimental COVID-19 vaccine developed by Taiwanese maker Adimmune Corp. has been given conditional approval to enter human trials, according to Taiwan's Food and Drug Administration (FDA) on Monday.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    172.30.142.197